Description:
LIK066 is a potent sodium-glucose transporter 1 and sodium-glucose transporter 2 inhibitor originated by Novartis Pharmaceuticals Corporation IC50 with value of 22.0 nM against human SGLT1 and 0.5 nM against human SGLT2. In Apr 2016, Novartis completed a phase II trial for Type 2 diabetes mellitus in USA.
- Molecular Weight:948.07
- Purity:98%
Molecular Formula:
C51H65NO16
Canonical SMILES:
CCC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC4=C(C=C3)OCCO4
InChI:
InChI=1S/C23H28O7/c1-2-14-4-5-15(23-22(27)21(26)20(25)19(12-24)30-23)11-16(14)9-13-3-6-17-18(10-13)29-8-7-28-17/h3-6,10-11,19-27H,2,7-9,12H2,1H3/t19-,20-,21+,22-,23+/m1/s1
InChIKey:
XFJAMQQAAMJFGB-ZQGJOIPISA-N
Solubility:
Soluble in DMSO
Appearance:
Powder
Application:
Type 2 diabetes mellitus
Storage: -20°C Freezer
Synonyms:
LIK-066; LIK 066; licogliflozin Más detalles se encuentran
aquí